Puma Biotechnology Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares.
View analyst ratings for Puma Biotechnology or view top-rated stocks.

Wall Street analysts have given Puma Biotechnology a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Puma Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Puma Biotechnology saw a drop in short interest in January. As of January 15th, there was short interest totaling 4,880,000 shares, a drop of 26.9% from the December 31st total of 6,680,000 shares. Based on an average trading volume of 547,200 shares, the short-interest ratio is presently 8.9 days. Approximately 14.5% of the shares of the company are short sold.
View Puma Biotechnology's Short Interest.

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Puma Biotechnology.

Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its quarterly earnings results on Wednesday, February, 24th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.07. Puma Biotechnology had a negative net margin of 23.86% and a negative trailing twelve-month return on equity of 451.50%.
View Puma Biotechnology's earnings history.

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PBYI stock has increased by 7.4% and is now trading at $9.96.
View which stocks have been most impacted by COVID-19.

7 equities research analysts have issued 1 year price objectives for Puma Biotechnology's shares. Their forecasts range from $9.00 to $17.00. On average, they expect Puma Biotechnology's share price to reach $13.14 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price.
View analysts' price targets for Puma Biotechnology or view top-rated stocks among Wall Street analysts.

Some companies that are related to Puma Biotechnology include Travere Therapeutics (TVTX), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPF), Olema Pharmaceuticals (OLMA), Zealand Pharma A/S (ZEAL), Ironwood Pharmaceuticals (IRWD), DiaMedica Therapeutics (DMCAF), Y-mAbs Therapeutics (YMAB), Supernus Pharmaceuticals (SUPN), MacroGenics (MGNX), Kiniksa Pharmaceuticals (KNSA), Ocular Therapeutix (OCUL), MannKind (MNKD) and Cytokinetics (CYTK).
View all of PBYI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Puma Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.53%), Renaissance Technologies LLC (4.18%), Jupiter Asset Management Ltd. (1.83%), Rice Hall James & Associates LLC (1.52%), Morgan Stanley (1.26%) and Northern Trust Corp (0.92%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Douglas M Hunt, Jay M Moyes, Maximo F Nougues, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends for Puma Biotechnology.

PBYI stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Panagora Asset Management Inc., JPMorgan Chase & Co., Credit Suisse AG, Russell Investments Group Ltd., Principal Financial Group Inc., Sei Investments Co., and Barclays PLC. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Douglas M Hunt, Jay M Moyes, Maximo F Nougues, Richard Paul Bryce, and Troy Edward Wilson.
View insider buying and selling activity for Puma Biotechnology or view top insider-selling stocks.

PBYI stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, Jupiter Asset Management Ltd., BlackRock Inc., Squarepoint Ops LLC, Strs Ohio, Rice Hall James & Associates LLC, and Prospera Financial Services Inc.
View insider buying and selling activity for Puma Biotechnology or or view top insider-buying stocks.

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PBYI stock can currently be purchased for approximately $9.96.

Puma Biotechnology has a market capitalization of $396.03 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis.

Puma Biotechnology employs 269 workers across the globe.

The official website for Puma Biotechnology is www.pumabiotechnology.com.

Puma Biotechnology is headquartered at 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]